Simultaneous delivery of gene and chemotherapeutics via copolymeric micellar nanoparticles to overcome multiple drug resistance to promote synergistic tumor suppression

Abstract

Combination of chemotherapy and small interfering RNA (siRNA)-based nanotherapeutics could cooperatively and effectively suppress multiple drug resistance in cancer development. Particularly, nano-delivery systems that efficiently encapsulate two or more therapeutic payloads to the tumor-targeted sites have been proven significantly. Here, we prepared a micellar nanoparticle formed by monomethoxy poly (ethylene glycol)–block–poly(ε-caprolactone)-block-poly(L-lysine)/cholesterol (mPEG-b-PCL-b-PLL/Chol, further abbr. as “P”). In this work, PCL as the hydrophobic core to encase doxorubicin and PLL as the cationic moiety to bind with negatively charged siRNA are used to achieve the co-delivery of therapies in one platform. The results showed that the micellar nanoparticle is capable of delivering siRNA and doxorubicin simultaneously to the same tumor cells, and consequently displays enhanced inhibition efficiency on MCF-7/ADR cells. Moreover, real-time polymerase chain reaction (RT-PCR) and Western blot experiments indicated that the co-delivery of micelleplex-delivering B-cell lymphoma 2 specific siRNA (siBcl) successfully down-regulated the expression of Bcl-2 protein, which triggers chemotherapy to be more sensitive to the cancer cells. Therefore, the strategy of co-delivering anticancer drug and siRNA showed promising potential in reversing drug resistance of tumor cells.

Keywords

Micellar nanoparticle multiple drug resistance co-delivery synergistic effect siRNA

Get full access to this article

View all access options for this article.

References

Uzgare

Kaplan

Greenberg

NM.

Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate 2003; 55: 128–139.

Bai

et al . Co-delivery of doxorubicin and tumor-suppressing p53 gene using a POSS-based star-shaped polymer for cancer therapy. Biomaterials 2015; 55: 12–23.

Kemp

Shim

Heo

et al . “Combo” nanomedicine: co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Adv Drug Deliv Rev 2016; 98: 3–18.

Pan

Chen

Nie

et al . In situ synthesis of ultrathin ZIF-8 film-coated MSNs for codelivering Bcl 2 siRNA and doxorubicin to enhance chemotherapeutic efficacy in drug-resistant cancer cells. ACS Appl Mater Interfaces 2018; 10: 33070–33077.

Sun

Chen

Xie

et al . Co-delivery of doxorubicin and anti-BCL-2 siRNA by pH-responsive polymeric vector to overcome drug resistance in in vitro and in vivo HepG2 hepatoma model. Biomacromolecules 2018; 19: 2248–2256.

Chen

Zhang

Wei

et al . Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009; 5: 2673–2677.

Lee

Hong

Bonner

et al . Self-assembled RNA interference microsponges for efficient siRNA delivery. Nat Mater 2012; 11: 316–322.

Kaps

Nuhn

Aslam

et al . In vivo gene-silencing in fibrotic liver by siRNA-loaded cationic nanohydrogel particles. Adv Healthcare Mater 2015; 4: 2809–2815.

Kay

MA.

State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 2011; 12: 316–328.

10.

Shen

Zhang

et al . Engineering functional inorganic-organic hybrid systems: advances in siRNA therapeutics. Chem Soc Rev 2018; 47: 1969–1995.

11.

Fahmy

Fong

Goyal

et al . Targeted for drug delivery. Mater Today 2005; 8: 18–26.

12.

Sun

Huang

Zhang

et al . A Pd corolla–human serum albumin–indocyanine green nanocomposite for photothermal/photodynamic combination therapy of cancer. J Mater Chem B 2018; 6: 6969–6976.

13.

Zhang

et al . Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-beta-cyclodextrin nanocarrier. Int J Nanomedicine 2015; 10: 3147–3162.

14.

Z-Y

Jin

Z-H

Zhan

et al . Advances in quantum dot-mediated siRNA delivery. Chin Chem Lett 2017; 28: 1851–1856.

15.

Ediriwickrema

Zhou

Deng

et al . Multi-layered nanoparticles for combination gene and drug delivery to tumors. Biomaterials 2014; 35: 9343–9354.

16.

Sun

Yan

et al . Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery. Biomaterials 2008; 29: 4348–4355.

17.

Sun

T-M

J-Z

Yao

Y-D

et al . Simultaneous delivery of siRNA and paclitaxel via a “Two-in-One” micelleplex promotes synergistic tumor suppression. ACS Nano 2011; 5: 1483–1494.

18.

Liu

Chen

et al . Biodegradable copolymers with identical cationic segments and their performance in siRNA delivery. J Control Release 2012; 159: 251–260.

19.

Yang

et al . ICG@ZIF-8: one-step encapsulation of indocyanine green in ZIF-8 and use as a therapeutic nanoplatform. Chin Chem Lett 2018; 29: 1421–1424.

20.

Shen

Mai

et al . High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. ACS Nano 2013; 7: 9867–9880.

21.

Oba

Miyata

Osada

et al . Polyplex micelles prepared from omega-cholesteryl PEG-polycation block copolymers for systemic gene delivery. Biomaterials 2011; 32: 652–663.

22.

Becker

Johnston

Caruso

Layer-by-layer-assembled capsules and films for therapeutic delivery. Small 2010; 6: 1836–1852.

23.

Jia

Cui

Bignon

et al . Reduction-responsive cholesterol-based block copolymer vesicles for drug delivery. Biomacromolecules 2014; 15: 2206–2217.

24.

Han

Tang

et al . Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. J Control Release 2012; 163: 136–144.

25.

Han

Kou

et al . Lipid nanoparticle-based co-delivery of epirubicin and BCL-2 siRNA for enhanced intracellular drug release and reversing multidrug resistance. Artif Cells Nanomed Biotechnol 2018; 46: 323–332.

26.

Simon

Shumiatcher

Yeung

et al . Bcl-2 Regulates reactive oxygen species signaling and a redox-sensitive mitochondrial proton leak in mouse pancreatic-cells. Endocrinology 2016; 157: 2270–2281.

27.

Reed

JC.

Apoptosis-based therapies. Nat Rev Drug Discov 2002; 1: 111–121.